First-line ADP-A2M4CD8 T-cell Receptor T-cell Therapy plus Pembrolizumab in Head and Neck Cancers: An Additional Cohort of the Phase 1 SURPASS Trial

ADP-A2M4CD8 is an autologous CD4+ and CD8+ T-cell therapy under investigation for treatment of advanced cancers in human leukocyte antigen (HLA)-A*02 –eligible participants. It expresses a genetically modified T-cell receptor (TCR) targeting melanoma-associated antigen A4 (MAGE-A4) and an additional CD8α co-receptor to increase functionality of CD4+ T cells. ADP-A2M4CD8 monotherapy has demonstrated an acceptable benefit-risk profile in the ong oing Phase 1 SURPASS trial (NCT04044859), with clinical responses in multiple tumor types in the late-line setting.

Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: A. Ho, A. Garcia-Consuegra, J. Saro, A. Sauer, S. Cristiani, F.E. Brophy, S. Streets, E. Norry, M. Gillison, J. Charlson, M. Bover, J. Zugazagoitia, E. Calvo, L. Ugidos, G. Bruixola, V. Moreno Garcia, D.S. Hong, J. Rubio-P érez, D.H. Aggen Tags: 252 Source Type: research